Head and neck cancer (HNC) and its treatment may negatively alter neurocognitive and speech functioning. However, the prevalence of neurocognitive impairment among patients with HNC before treatment is poorly studied, and the association between neurocognitive and speech functioning is unknown, which hampers good interpretability of the effect of HNC treatment on neurocognitive and speech function.
B eing able to communicate is an important factor that predicts quality of life. 1, 2 To communicate, speakers access information in long-term memory, use executive function, 3 and prepare and execute a motor speech program. 4, 5 Therefore, neurocognitive function and motor speech processes are interrelated in the production of speech. Neurocognitive and speech functioning represent important domains of investigation in patients with head and neck cancer (HNC) because HNC and its treatment may alter speech 6,7 and neurocognitive functions. 8, 9 Research has indicated that neurocognitive and speech problems may already be present in patients with HNC at baseline (ie, before treatment). [10] [11] [12] [13] Speech problems at baseline have been detected using selfreport questionnaires 11 and through objective assessments from recorded speech. 10 For example, 61% of patients with HNC reported that they had speech problems at baseline, with greater difficulties in oral and oropharyngeal cancer relative to laryngeal and hypopharyngeal cancer. 11 Using objective measures from recorded speech, abnormal intelligibility, nasality, and articulation were found in 17% to 37% of the patients, with oral cavity tumor cases scoring more poorly than oropharyngeal tumor cases. 10 Both self-reported and objective measures of speech impairment correlated with patients' emotional distress or perceived quality of life.
10,11
Regarding neurocognitive functioning, much less is known. To date, few studies [12] [13] [14] have reported the prevalence of neurocognitive impairment (ie, clinically relevant deficits compared with an age-and education-adjusted normative sample) as measured objectively before treatment among patients with HNC. These studies found between 21% and 36% neurocognitive impairment 12,14 using several neuropsychological tests, with about 55% using the Montreal Cognitive Assessment (MoCA).
13
Besides decreasing quality of life, a high prevalence of neurocognitive impairment among this population before treatment may complicate patient-clinician interaction and alter treatment adherence. 13 These factors emphasize that better characterization of pretreatment neurocognitive impairment is critical. The baseline neurocognitive and speech deficits observed in this population may have different and mutual etiologies. Cognitive deficits originate at the level of the central nervous system, but their etiological mechanism remains unclear. 12 In contrast, motor speech deficits are associated with damage to the organs and muscles involved in speaking (eg, speech problems are associated with tumor location 11 ). However, speaking not only involves peripheral motor function, including the vocal tract and speech organs, but also engages multiple cognitive processes, such as long-term memory access 4, 5 and executive function. Being able to communicate is an important predictor of quality of life. 1, 2 Given that both speech and neurocognitive functions may already be affected before treatment in patients with HNC, examining these functions in one study sample provides valuable information about this population. To date, no study has reported on neurocognitive and speech functioning before treatment in the same group of patients. The present study focused on neurocognitive functioning and speech before treatment using prospective data from a large sample collected in a nationwide, multicenter setting (Netherlands Quality of Life and Biomedical Cohort Study in Head and Neck Cancer [NET-QUBIC] project). First, we documented neurocognitive functioning as measured objectively and subjectively in patients with HNC before treatment. Second, we investigated demographic, behavioral, and disease-related features associated with low neurocognitive functioning in patients with HNC. Third, we characterized for the first time to date the association between neurocognitive and speech functioning in this population.
Methods

Patients
This research was part of a large, ongoing prospective cohort study investigating long-term quality of life in patients with HNC and their caregivers (NET-QUBIC study [https://researchers .kubusproject.nl/general-information]). For the present analyses, baseline data (collected before the start of treatment) were used from the first data release, which included 254 newly diagnosed patients with HNC. Clinical and demographic characteristics, alcohol consumption, and smoking status were collected via self-report questionnaires and medical records. The characteristics of this group of patients are listed in the Table. Patients were recruited from 8 hospitals in different regions in the Netherlands (Radboud University Medical Center, Nijmegen; Amsterdam UMC, Amsterdam; University Medical Center, Utrecht; University Medical Centre Groningen, Groningen; Erasmus MC, Rotterdam; Rijnstate Hospital, Arnhem; Noordwest Ziekenhuisgroep, Alkmaar; and Medisch Centrum, Leeuwarden). Patients meeting the following inclusion criteria were invited to participate: 18 years or older; able to write, read, and speak Dutch fluently; newly diagnosed with HNC (to increase homogeneity, restricted to larynx, hypopharynx, oropharynx, oral cavity, and neck metastasis of unknown primary tumor with proven squamous cell histology [all stages]); and previously untreated and currently planned treatment with curative intent according to standard treatment guidelines, including surgery, radiotherapy, and/or systemic antineoplastic therapy. Exclusion criteria were nasopharyngeal or skin cancers (due to their low occurrence), tumors of the salivary glands, lymphoma thyroid cancer, or severe psychiatric comorbidities (eg, schizophrenia, Korsakoff syndrome, and severe dementia). Comorbidity scores were defined according to the Adult Comorbidity Evaluation 27 (ACE-27).
15 All participating patients signed an informed consent.
Ethical approval was obtained by the coordinating center (Medical Ethical Committee Vrije UMC), and local approval was obtained for each individual center (a more detailed explanation about the procedure and recruitment has been previously published 16 ).
Assessments
Assessments were conducted at the hospital and/or the patient's home by trained assessors. Cognitive assessment in- tionnaire was administered as a measure of self-perceived speech functioning, with questions about speech problems (eg, "My speech makes it difficult for people to understand me" and "The intelligibility is unpredictable"). The SHI is a valid, reliable speechspecific quality-of-life questionnaire that helps identify the nature and severity of the problems experienced by patients with HNC. 22 A total SHI can be calculated ranging from 0 to 120, with higher scores indicating more speech problems and with a cutoff value of 6 being able to identify patients with speech problems in daily life. In addition, 2 subscales can be derived that reflect psychosocial function and speech function.
Statistical Analysis
Although 254 patients met the inclusion and exclusion criteria, not all patients completed all of the neuropsychological tests or the self-report questionnaires (mainly due to logistic reasons or the patients' own withdrawal from participation for that part because patients could choose in which parts of the NET-QUBIC study they wanted to participate). Missing data for each individual test were identified, and for each analysis only completed cases at the analysis-specific level were included. For all results, we report the sample size on which each of the statistical tests was based. Available normative data were used to convert the patients' results on the neuropsychological tests into standardized T scores (mean [SD] , 50 [10]), adjusted for age, sex, and education (HVLT 18 ; TMT
17
; and verbal fluency, letters B, D, and H, norms derived from own databases). Patients for whom demographic information was unknown were excluded. The proportions of patients performing more than 1 SD and more than 2 SDs below the age-, sex-, and education-adjusted norm were quantified. Neurocognitive impairment was classified as mild to moderate (T score, 30-39 [ie, 1- 
Results
The characteristics of 254 newly diagnosed patients with HNC are summarized in the Table) , no clinically meaningful differences were found for age (mean, 62.7 vs 60.9 years, respectively), sex distribution, education, literacy, tumor stage and tumor site, or smoking status. The distribution of comorbidity scores did differ between the 2 groups. Those who completed all assessments more often had severe comorbidity scores or no comorbidity (17.4% severe, 16.8% moderate, 30.3% mild, and 35.5% none) relative to those who did not complete all tests (13.4% severe, 17.1% moderate, 48.8% mild, and 20.7% none). Twenty-eight patients did not complete the CFQ and the SHI, but they completed all objective neurocognitive tests. No differences were found in the scores between the 2 groups for any test (all 95% CIs overlap with zero). Thirty-two patients did not complete any of the objective neurocognitive tests, but they completed both the CFQ and the SHI. No differences were found in the scores between the 2 groups (all 95% CIs overlap with zero).
As shown in Figure 1 , moderate to severe impairment was found in 15.0% (32 of 214) of the patients in delayed recall, 6.0% (13 of 215) in letter fluency, 4.7% (10 of 212) in psychomotor speed (TMT-A), and 5.7% (12 of 211) in executive functioning (TMT-B). Mild to moderate impairment was found in 26.2% (56 of 214) of the patients in delayed recall, 24.2% (52 of 215) in letter fluency, 12.3% (26 of 212) in psychomotor speed, and 20.4% (43 of 211) in executive functioning. Figure 2 summarizes the patients' self-reported cognitive functioning (n = 208) and speech (n = 209) overall and by tumor site. For the CFQ, 7.2% (15 of 208) of the patients reported experiencing above-average failure; for the total SHI, 42.6% (89 of 209) of the patients scored in the impaired range for self-perceived speech problems (ie, above the cutoff value of 6).
Patient-reported and objective neurocognitive functioning was not associated with any variable (demographic, behavioral, or disease related): the models' adjusted R 2 values were −0.006 for the CFQ, 0.025 for the SHI, −0.016 for delayed recall, −0.018 for letter fluency, 0.026 for psychomotor speed, and −0.003 for executive functioning). Furthermore, no significant associations were found in regression models with additional variables of literacy, tumor site, comorbidity score, and smoking status: the models' adjusted R 2 values were −0.035 for the CFQ, 0.116 for the SHI, −0.052 for delayed recall, 0.034 for letter fluency, 0.068 for psychomotor speed, and −0.051 for executive functioning). The results of these models are summarized in eTables 1, 2, 3, and 4 in Supplement 2. Objective and patient-reported neurocognitive measures did not correlate significantly (all Spearman rank correlation coefficients were between −0.026 and 0.155, and 95% CIs overlapped with zero except for TMT-A [95% CI, 0.009-0.289]). Objective neurocognitive measures did not correlate significantly with patient-reported speech outcome (all Spearman rank correlation coefficients were between 0.124 and 0.172, and 95% CIs overlapped with zero except for TMT-B [95% CI, 0.018-0.321]). Patient-reported neurocognitive functioning was significantly correlated with speech functioning (total SHI), with a small effect size (ρ = 0.266; 95% CI, 0.126-0.400) (n = 195), as shown in Figure 3 (also by tumor site). When the analyses were restricted to the group that completed all tests (n = 162), the exact same association was observed (ρ = 0.266). The SHI 
Discussion
Using prospective data from a large sample collected nationwide, the present study documented the prevalence of neurocognitive and speech impairment before treatment among patients newly diagnosed as having HNC. Moreover, we report for the first time to our knowledge an association between patient-reported neurocognitive and speech functioning and objectively measured neurocognitive functioning.
Regarding speech, almost half of the patients reported selfperceived speech in the impaired range. This prevalence is similar to what has been previously reported.
11 Self-perceived neurocognitive failure was observed in a small subgroup of the patients.
The prevalence of neurocognitive impairment we report herein is similar to or slightly higher than that previously reported using comparable neuropsychological tests, 12,14 with additional similarity in age, sex, and education between the samples. However, the sample size is more than 3 times larger in our study, and our data were collected in a multicenter setting. Furthermore, the prevalence we report is lower than that previously reported using the MoCA, 13 with which more than half of the patients were found to have mild cognitive impairment. However, the MoCA has both a lower sensitivity and a lower specificity than the neuropsychological tests we used. 26, 27 In addition, the MoCA has limited adjustment for education level. 27 These 2 factors could explain the discrepancy between our results and the findings based on that assessment. The rates of severe to moderate impairment we observed (4.7%-15.0%) are higher than what can be expected in the healthy population (in which by definition 2.3% of the population performs ≥2 SDs below the normative mean). Therefore, there is a substantial subgroup of patients with HNC who are seen with moderate to severe cognitive impairment already at baseline, which could not be explained by demographic variables, such as age, sex, and education, or by alcohol consumption or disease stage (as well as literacy, tumor site, comorbidity score, and smoking status as summarized in eTables 1, 2, 3, and 4 in Supplement 2). Understanding the reason why this subgroup is seen with neurocognitive impairment before the start of treatment is important because treatments may trigger cerebrovascular disease 28 and consequently influence neurocognitive function.
As mentioned previously, it remains an open question whether the neurocognitive impairment is caused by biological processes triggered by the cancer and/or by risk factors that alter both cognitive functioning and the pathology itself. 12 For example, Bond et al 12 found an association between smoking and alcohol abuse on the one hand and between smoking and global neurocognitive deficit on the other hand. However, the association with alcohol abuse was not significant at the level of the individual neurocognitive measures. In our sample, performance on the neuropsychological measures could not be explained by alcohol consumption. Additional large-scale studies focusing on this question are needed. Longitudinal studies on neurocognitive changes after treatment, enabling comparison across different treatment types, may also help elucidate this question because surgery alone is expected to have a smaller influence on the central nervous system than chemotherapy or radiotherapy.
Limitations
Our study has some limitations. We did not include objective measures of speech functioning, but they are necessary for further understanding what alters a patient's communicative participation. In addition, we did not have performance validity measures that would enhance the interpretation of the neuropsychological tests (eg, in helping exclude the possibility that low performance on the neuropsychological tests was not due to a lack of effort put forth by the individuals when performing the tests). Our study also lacks specific control data, making it more difficult to interpret the results in light of risk factors for neurocognitive decline.
Conclusions
Understanding impairment in neurocognitive functioning at baseline, as well as in relation to speech function, is important not only in itself (eg, for patient counseling and education and for treatment decision making) but also for understanding treatmentrelated changes. Previous research examining the decline in neurocognitive function due to cancer therapy has been criticized for a lack of baseline data. 29 Our study is the first to date to systematically examine the association between patient-reported neurocognitive functioning and patient-reported speech functioning already at baseline. We found an association, albeit weak, between the patient-reported outcomes of neurocognitive functioning and speech functioning. This association was especially prominent among the patients with laryngeal cancer in our sample. This group does not show notably high rates of patientreported cognitive failure, but the rate of patient-reported speech impairment had a larger spread and generally higher values. An important question for future research is whether this group is particularly vulnerable to treatment influences. Furthermore, it is possible that individuals who experience more neurocognitive failure also have more communication difficulty. This interpretation is further supported by the finding herein that the psychosocial function subscale of the SHI better explains the variance in patient-reported neurocognitive functioning than does the speech function subscale of the SHI. Overall, the data suggest that patient-reported neurocognitive and speech functioning do dissociate but may interact at the level of daily life situations, shaping the patients' perception of their functioning. This association merits further investigation because it may hold important clues to understanding patient-clinician interaction as well as the patients' perceived communicative participation and quality of life. This pre-registration is not yet public. This anonymized copy (without author names) was created by the author(s) to use during peer-review. A non-anonymized version (containing author names) will become publicly available only if an author makes it public. Until that happens the contents of this pre-registration are confidential.
1) Have any data been collected for this study already?
No, no data have been collected for this study yet 2) What's the main question being asked or hypothesis being tested in this study?
Speech and neurocognitive function are important domains of investigation in head and neck cancer (HNC) patients. Research has also indicated that speech and neurocognitive problems may already be present in HNC patients at baseline, prior to treatment (Bond et al., 2012; Borggreven et al., 2007; Cnossen et al., 2012) . A preivous study reporting on cognitive impairment pre-treatment did not control for effects of substance abuse (Bond et al., 2012) . Moreover, self-reported neurocognitive function had a substantial floor effect for this measure, preventing any conclusions about self-perceived neurocognitive function in this group (Bond et al., 2012) .
Neurocognitive function and speech are intertwined in speaking and both seem to show pre-treatment deficits in HNC patients. To date, no study has reported on baseline in speech and (self-reported and objective) neurocognitive function in the same group of patients.
The proposed study has the following aims:
(1) Document neurocognitive function, as measured objectively and through patients' self-report, pre-treatment in HNC patients using data from the NET-QUBIC Kubus project (2) Identify demographic (gender, age, education, literacy), behavioural (alcohol and drug abuse), and disease-related (tumour location and stage)
features associated with low neurocognitive function in HNC patients. We hypothesise that substance abuse will be a strong predictor of cognitive function. Aim (1): normative data will be used to convert the patients' scores of the neuropsychological tests into t-scores, adjusted for age and education. A global deficit score will be calculated as the average of the t-scores converted to deficit scores (cf. Bode et al., 2012) . The relationship between self-perceived and objectively measured cognitive function will be assessed with Spearman's correlation analysis for each variable separately, multiple comparisons corrected via the Holm-Bonferroni method, and for the global deficit score.
Aim (2): LASSO regression will be used to assess the relative contribution of demographic (Gender, age, education, literacy) , behavioural (alcohol and drug abuse), and disease-related (tumour site and location) factors on the global deficit score. Of particular interest is the extent to which alcohol abuse can explain low cognitive functioning in the HNC patients.
Aim ( This document describes changes in the manuscript's analyses relative to the pre-registered analyses.
1) The original plan was to calculate a global deficit score and use it to correlate with patient-reported neurocognitive functioning, in addition to the individual neurocognitive tests. Upon reflection, this score seemed less meaningful than the individual tests themselves, so this analysis was not performed.
2) The original plan did not include the subscales of the Speech Handicap Index (SHI). However, given that a relationship was found between patientreported outcomes (i.e., total SHI score and cognitive failures score), additional analyses were included for the SHI subscales, which reflect psychosocial and speech function separately. This analysis was intended to find additional support for the hypothesis that the correlation between the patient-reported outcomes reflects a more neurocognitive/psychosocial relationship, rather than a peripheral, motor-speech one.
3) The original plan was to perform LASSO regression using demographic (gender, age, education, literacy), behavioural (alcohol and drug abuse), and disease-related (tumour site and location) factors on the global deficit score. However, LASSO regression proved unsuitable for the present dataset due to sample size (i.e., still too small for this type of statistical analysis). In addition, drug abuse and literacy did not show enough variance to be included as predictors in the model. Given that we did not calculate a global deficit score, the regression analyses were conducted on the individual neuropsychological tests instead.
All additional analyses reported in the manuscript were added during the review process Reference values were: comorbidity score of "None"; Literacy score of "Excellent (mother tongue)"; smoke score of "Never"; and hypophraynx tumor site. For sex, women are the reference value (treatment coding, women = 0, men = 1). 
